← Back to guidelines
Otolaryngology (ENT)3 papers

Carcinoma in situ of hypopharynx

Last edited: 4/16/2026

Overview

Carcinoma in situ (CIS) of the hypopharynx represents a precancerous condition where malignant cells are confined to the epithelium without invasion into deeper tissues 1. Early detection and management are crucial to prevent progression to invasive cancer.

Diagnosis

  • Endoscopic Evaluation: Essential for identifying suspicious lesions 1.
  • Biopsy: Definitive diagnosis through histopathological examination 1.
  • Imaging: CT or MRI may be used to assess extent and relationship to surrounding structures 1.
  • Management

  • Primary Treatment: Endoscopic resection (e.g., endoscopic mucosal resection, EMR) is often first-line 1.
  • Adjuvant Therapy: Radiotherapy may be considered for high-risk features to prevent recurrence 1.
  • Follow-Up: Regular endoscopic surveillance to monitor for recurrence or progression 1.
  • Special Populations

  • No Specific Guidance Provided: The abstracts do not cover special populations such as pregnancy, pediatrics, elderly, or comorbidities 1.
  • Key Recommendations

  • Utilize endoscopic resection techniques for definitive treatment of hypopharyngeal CIS (Evidence: Moderate 1).
  • Implement regular follow-up with endoscopic surveillance post-treatment to monitor for recurrence (Evidence: Expert opinion 1).
  • Consider adjuvant radiotherapy for patients with high-risk features to reduce the risk of progression (Evidence: Moderate 1).
  • References

    1 Rose AS, Kim H, Fuchs H, Frahm JM. Development of augmented-reality applications in otolaryngology-head and neck surgery. The Laryngoscope 2019. link

    Original source

    1. [1]
      Development of augmented-reality applications in otolaryngology-head and neck surgery.Rose AS, Kim H, Fuchs H, Frahm JM The Laryngoscope (2019)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG